TriangleFOR PATIENTS · SOURCE READING
Treatment of Untreated Acute Myeloid Leukemia
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Standard treatment of untreated acute myeloid leukemia (AML) during the remission induction phase depends on the subtype of AML and may include:
Source links and citations
combination chemotherapy that includes cytarabine
Source links and citations
combination chemotherapy with targeted therapy (midostaurin or quizartinib), for people whose AML has a mutation in the FLT3 gene
Source links and citations
combination chemotherapy with the targeted therapy drug gemtuzumab ozogamicin
Source links and citations
intrathecal chemotherapy (cytarabine or methotrexate), for central nervous system (CNS) leukemia
Source links and citations
supportive care
Source links and citations
For older adults or people who are unable or unwilling to receive intensive chemotherapy, the following may be continued as long as the person benefits or until toxic effects occur:
Source links and citations
targeted therapy (enasidenib, gilteritinib, glasdegib, ivosidenib, or venetoclax)
Source links and citations
low-dose chemotherapy (azacitidine, low-dose cytarabine, or decitabine)
Source links and citations
targeted therapy with low-dose chemotherapy
intrathecal chemotherapy, for CNS leukemia
supportive care
Learn more about these treatments in the Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice